RPG Life Sciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹212 Cr +16.5% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
RL

RPG Life Sciences Ltd

Q1 FY27Pharmaceuticals & Biotechnology

RPG Life Sciences Q1 FY27: Revenue ₹195.7 Cr, PAT ₹30.8 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹196Cr
+16% YoY
+10.7% QoQ
Net profit
₹31Cr
+19.2% YoY
+3.3% QoQ
Margin
22%
+1 pp YoY
+3 pp QoQ

Based on RPG Life Sciences Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,900
Market cap₹4.6K Cr
P/E39.7

The short version

Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] - Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18] - Q1 FY27 PAT: ₹30.8 EBITDA: ₹41.5 crores in Q1 FY27, up 17.0% from ₹35.4 crores in Q1 FY26 - EBITDA Margin: 21.2% in Q1 FY27, slightly up from 21.0% in Q1 FY26 - Revenue from Operations: ₹195.7 crores in Q1

From RPG Life Sciences Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18]
  • Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18]
  • Q1 FY27 PAT: ₹30.8 crores, up 17.0% YoY (Q1 FY26: ₹26.3 crores) [Page 18]
  • Domestic Formulations sales: ₹132.5 crores, up 14.8% YoY (Q1 FY26: ₹115.4 crores) [Page 19]

2 more points from RPG Life Sciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Rs 185+ crores capex infused since FY22 to build a modern, state-of-the-art plant with approvals from EU, TGA, PMDA, etc. (Page 24)
  • Evaluation ongoing for varied opportunities to improve manufacturing productivity (Page 24)
  • Ankleshwar multipurpose formulation plant equipped for low humidity products serving domestic and emerging markets; strong production capacity (Page 8)
  • API manufacturing facility in Navi Mumbai with three units including a dedicated immunosuppressant unit, catering to regulated markets (Page 8)

2 more points from RPG Life Sciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.

RPG Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

RPG Life Sciences Ltd Q1 FY27 results — key figures

RPG Life Sciences Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue196169+16%177+10.7%
Operating profit (EBITDA)4435+25.7%33+33.3%
Operating margin22%21%+1 pp19%+3 pp
Profit before tax4135+17.1%40+2.5%
Net profit (PAT)3126+19.2%30+3.3%
EPS (₹)18.4915.90+16.3%18.08+2.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were RPG Life Sciences Ltd Q1 FY27 results?

Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] - Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18] - Q1 FY27 PAT: ₹30.8 EBITDA: ₹41.5 crores in Q1 FY27, up 17.0% from ₹35.4 crores in Q1 FY26 - EBITDA Margin: 21.2% in Q1 FY27, slightly up from 21.0% in Q1 FY26 - Revenue from Operations: ₹195.7 crores in Q1

What is RPG Life Sciences Ltd share price analysis?

RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.

Is RPG Life Sciences Ltd planning capital expenditure?

Rs 185+ crores capex infused since FY22 to build a modern, state-of-the-art plant with approvals from EU, TGA, PMDA, etc.

Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.